SQ2 Stock Overview
KetamineOne Capital Limited, a next generation wellness company, focuses on ketamine assisted therapy and psychedelic medicines through operating healthcare clinics in North America.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Wellbeing Digital Sciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.003 |
| 52 Week High | CA$0.059 |
| 52 Week Low | CA$0.0005 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -80.00% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| SQ2 | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.7% | 0.4% |
| 1Y | -80.0% | 3.8% | 3.9% |
Return vs Industry: SQ2 underperformed the German Healthcare industry which returned 10.6% over the past year.
Return vs Market: SQ2 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| SQ2 volatility | |
|---|---|
| SQ2 Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 5.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: SQ2 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SQ2's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Najla Guthrie | www.ketamine.one |
KetamineOne Capital Limited, a next generation wellness company, focuses on ketamine assisted therapy and psychedelic medicines through operating healthcare clinics in North America. The company was formerly known as Myconic Capital Corp. and changed its name to KetamineOne Capital Limited in June 2021. KetamineOne Capital Limited was founded in 2017 and is headquartered in Vancouver, Canada.
Wellbeing Digital Sciences Inc. Fundamentals Summary
| SQ2 fundamental statistics | |
|---|---|
| Market cap | €1.69m |
| Earnings (TTM) | -€25.21m |
| Revenue (TTM) | €6.44m |
0.0x
P/S Ratio0.0x
P/E RatioIs SQ2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SQ2 income statement (TTM) | |
|---|---|
| Revenue | CA$6.44m |
| Cost of Revenue | CA$6.02m |
| Gross Profit | CA$424.24k |
| Other Expenses | CA$25.63m |
| Earnings | -CA$25.21m |
Last Reported Earnings
Jul 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 6.59% |
| Net Profit Margin | -391.32% |
| Debt/Equity Ratio | -884.5% |
How did SQ2 perform over the long term?
See historical performance and comparison